Response to HCQ
In this study, there were 37 patients who had records of platelet counts
at 3 months from HCQ initiation, and 5 patients were not involved in
this analysis because of missing data. 21 (56.8%) patients achieved
CR/R at 3 months from HCQ initiation, and 16 (43.2%) patients had no
response to the treatment. According to the response to HCQ at 3 months
from initiation, we divided the 37 patients into two groups: the
response group and the no response group. Differences between the two
groups are listed in Table 2. There was no difference in the presence of
symptoms associated with autoimmune diseases, baseline ANA positivity,
antiphospholipid antibodies positivity, Low C3/C4, and autoimmune
disease progression between the two groups. In the response group,
71.4% (15/21) of patients achieved long-term response (including 2
achieved R and 13 achieved CR at 12 months), and 9.5% (2/21) of
patients lost CR/R. Most of patients with no response to HCQ received
monotherapy of HCQ (10/16, 62.5%), while most of patients with response
to HCQ received combined therapy (17/21, 81.0%).